Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Newly discovered link between traumatic brain injury in children and epigenetic changes could help personalize treatment for recovering kids - 2A Manual for the Right SUV for Seniors
- 3Fireball sightings are surging across the US — here's what's really going on
- 4Step by step instructions to Explore the Close to home Consequence of Cellular breakdown in the lungs
- 5A hospital discharged a woman in labor. This lawmaker wants change.
- Putting resources into Yourself: Self-awareness Techniques
- Meet the Stars of the Feline World: Well known Pet Feline Varieties
- What is a Trump Gold Card? U.S. launches $1 million immigration visas
- Old video misrepresented as senior Sri Lankan ruling party member criticising president over fuel shortage
- Bestselling author Colleen Hoover reveals cancer journey
- NASA's Artemis II launch leaves Americans in awe: 'We're going back to the frickin' moon!'
- Figure out How to Consolidate Cutting edge innovations in Senior's SUVs
- 7 Fast Approaches to Let loose Space on Your Telephone in a flash
- Nigeria’s return to Windsor castle signals new era in UK economic partnership
